FDA Approves Denali's AVLAYAH for Hunter Syndrome, First Brain-Penetrant Therapy in 20 Years
DNLI has more than doubled off its 52-week low of $10.57.
Summary
Denali Therapeutics has secured accelerated FDA approval for AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter Syndrome (MPS II). This marks a significant breakthrough, being the first new FDA-approved treatment for the condition in nearly two decades and the first biologic specifically designed to cross the blood-brain barrier for this indication. The approval also comes with a Rare Pediatric Disease Priority Review Voucher. This milestone validates Denali's proprietary TransportVehicle™ platform and is expected to open a new, material revenue stream for the company, addressing a critical unmet medical need. Investors will now focus on the commercial launch and the ongoing Phase 2/3 COMPASS study, which is designed to provide confirmatory evidence for continued approval.
At the time of this announcement, DNLI was trading at $21.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $10.57 to $23.77. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.